REGN Q3 2019 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.7B+4.8% YoY

Gross Profit

$1.5B84.0% margin

Operating Income

$739M42.4% margin

Net Income

$670M38.4% margin

EPS (Diluted)

$5.86

QoQ Revenue Growth

+10.5%

Cash Flow

Operating Cash Flow

$557M

Free Cash Flow

$436M

Stock-Based Comp.

$117M

Balance Sheet

Total Assets

$13.9B

Total Liabilities

$3.4B

Stockholders' Equity

$10.5B

Cash & Equivalents

$1.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.7B	$1.7B	+4.8%
Gross Profit	$1.5B	$1.5B	-3.5%
Operating Income	$739M	$627M	+17.8%
Net Income	$670M	$595M	+12.6%

Revenue Segments

Product

$1.2B100%